dorsaVi Limited (DVL) AI Stock Analysis

• Market Cap: AU$11.70M
• Dividend Yield: N/A
• Average Volume (3M): 2.38M
• Price to Earnings (P/E): ―
• Beta (1Y): -0.11
• Revenue Growth: -8.28%
• EPS Growth: 35.71%
• Country: AU
• Employees: 34
• Sector: Technology
• Sector Strength: 79
• Industry: Hardware, Equipment & Parts
• EPS (TTM): >-0.01
• Shares Outstanding: 731,237,900
• 10 Day Avg. Volume: 5,313,156
• 30 Day Avg. Volume: 2,382,800
• PEG Ratio: -0.36
• Price to Book (P/B): 3.45
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -9.25
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 46 Neutral
• Price Target: AU$0.00 ▼(-100.00%Downside)

dorsaVi Limited faces significant financial challenges with declining revenue, persistent losses, and negative cash flows, which heavily impact the stock's score. Despite some positive technical analysis signals suggesting short-term bullish momentum, the negative P/E ratio and lack of dividend yield present valuation concerns. Overall, the financial performance issues are the most significant factor, overshadowing other components.

dorsaVi Limited Business Overview & Revenue Model

Company Description

dorsaVi Ltd engages in the development and sale of motion analysis technologies in Australia, Europe, and the United States. The company provides ViMove+, a clinical and sports solutions; ViSafe, a wearable sensor technology that tracks, analyzes, and reports how workforce moves and reviews and pinpoints unsafe work practices that leads to workplace injury; and myViSafe technology for organizations and on-site clinicians to identify and mitigate injury risk in the workplace and drive behavioral changes. It also offers ViPerform, a wearable and wireless movement sensor technology that offers objective data to assess risk of sport injury, and guides athletic training and recovery programs; telehealth solutions; and professional suites. dorsaVi Ltd was incorporated in 2008 and is based in Oakleigh South, Australia.

How the Company Makes Money

dorsaVi Limited generates revenue through the sale of its wearable sensor devices and subscription-based access to its software platforms. The company offers its products and services to healthcare providers, sports professionals, and organizations focused on workplace safety, which utilize the technology for injury prevention, rehabilitation, and performance optimization. Additionally, dorsaVi may form strategic partnerships with healthcare institutions, sports organizations, and corporate clients, providing customized solutions that contribute to its earnings. Revenue is also supported by ongoing research and development efforts that enhance the company's product offerings, leading to potential increases in sales and subscription renewals.

dorsaVi Limited Financial Statement Overview

Summary

dorsaVi Limited is facing significant financial challenges with declining revenues, persistent losses, and negative cash flows. While the company maintains a manageable level of debt, the operational inefficiencies and inability to generate positive cash flows pose serious concerns.

Income Statement

dorsaVi Limited has experienced a decline in revenue and profitability over recent years. The negative gross profit margin indicates the company is selling its products below cost. With consistent negative EBIT and EBITDA margins, the company is struggling to cover its operating expenses. Additionally, the company has not shown any revenue growth in the past year, highlighting significant challenges in its business model and market conditions.

Balance Sheet

The company's balance sheet shows a relatively low debt-to-equity ratio, which suggests moderate leverage. However, the persistent losses have eroded equity over the years, and the return on equity remains negative, indicating inefficiencies in using shareholder funds. The equity ratio shows that equity is a small portion of total assets, hinting at potential solvency issues.

Cash Flow

The company has consistently experienced negative free cash flow, indicating it is not generating enough cash to cover its capital expenditures. The operating cash flow is also negative, reflecting challenges in generating cash from core operations. The free cash flow and operating cash flow to net income ratios are unfavorable, suggesting poor cash conversion efficiency.

Breakdown
TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
1.35M	1.30M	1.75M	2.35M	1.87M	2.02M
	Gross Profit
576.91K	1.18M	-798.43K	-1.45M	-1.74M	-2.21M
	EBIT
-1.38M	-1.69M	-2.37M	-2.83M	-3.08M	-3.96M
	EBITDA
-1.45M	-1.60M	-1.88M	-1.53M	-2.29M	-6.84M
	Net Income Common Stockholders
-1.14M	-1.25M	-1.82M	-1.54M	-2.41M	-7.59M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.24M	478.10K	878.72K	449.70K	2.80M	1.69M
	Total Assets
2.62M	2.18M	2.69M	3.36M	5.42M	3.83M
	Total Debt
131.48K	190.17K	321.85K	1.18M	1.18M	1.91M
	Net Debt
-1.11M	-287.93K	-556.87K	731.43K	-1.61M	226.63K
	Total Liabilities
938.19K	1.16M	1.01M	2.13M	2.95M	3.37M
	Stockholders Equity
1.68M	1.02M	1.68M	1.22M	2.48M	459.03K
Cash Flow		Free Cash Flow
-711.76K	-622.08K	-1.02M	-2.25M	-2.36M	-2.97M
	Operating Cash Flow
-707.75K	-600.90K	-967.41K	-2.15M	-2.27M	-2.18M
	Investing Cash Flow
-10.02K	-21.18K	-51.65K	-100.34K	-85.41K	-788.80K
	Financing Cash Flow
1.07M	227.06K	1.45M	-92.25K	3.47M	1.89M

dorsaVi Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	62 Neutral	$11.80B	10.10	-7.47%	2.99%	7.37%	-8.16%
RHT	61 Neutral	AU$17.47M	140.00	-3.11%	―	89.13%	69.57%
RAC	54 Neutral	AU$197.19M	―	-37.20%	―	―	32.02%
PYC	53 Neutral	AU$691.16M	―	-112.97%	―	―	-84.82%
DVL	46 Neutral	AU$11.70M	―	-74.01%	―	-8.28%	35.71%
IPDQF		$39.43M	―	-51.08%	―	―	―
BOT	53 Neutral	AU$588.26M	―	-56.99%	―	10.76%	-195.89%

dorsaVi Limited Corporate Events

dorsaVi Limited Announces Proposed Issue of 20 Million Securities

dorsaVi Limited has announced a proposed issue of 20 million new securities, specifically options expiring three years from issuance at an exercise price of $0.02. This move is part of a strategic placement aimed at enhancing the company’s financial positioning and operational capabilities, potentially impacting its market presence and offering benefits to stakeholders through increased capital resources.

dorsaVi Limited Announces Proposed Securities Issue

dorsaVi Limited announced a proposed issue of 60,000,000 ordinary fully paid securities, with the issuance date set for August 1, 2025. This move is part of a placement or other type of issue, which may impact the company’s market positioning by potentially increasing its capital base and providing additional resources for growth and development.

dorsaVi Secures Exclusive License for Advanced RRAM Technology from NTU Singapore

dorsaVi Limited has secured an exclusive worldwide license for advanced resistive random-access memory (RRAM) technology from NTU Singapore. This strategic acquisition is set to enhance dorsaVi’s sensor technology, offering improved efficiency and extended battery life, positioning the company for growth in high-value markets such as elite sports, rehabilitation, and industrial automation. The integration of RRAM technology into dorsaVi’s products is expected to redefine wearable technology capabilities, providing a competitive edge in the industry.

dorsaVi Limited Initiates Trading Halt for Major Announcement

dorsaVi Limited has requested a trading halt on its securities pending an important announcement regarding a Worldwide Exclusive RRAM Licence Agreement and a capital raising initiative. This move is aimed at managing its continuous disclosure obligations and is expected to impact the company’s market operations by potentially enhancing its technological capabilities and financial position.

dorsaVi Expands Reach with New SANO Health Partnership

dorsaVi has signed a three-year agreement with SANO Health, a leader in mining health solutions, to extend the use of its ViSafe+ technology across remote mining sites in Australia. This partnership aims to enhance dorsaVi’s product offerings in high-risk industries like mining and transport, allowing the company to expand its market reach both domestically and internationally, while providing SANO Health with the tools to improve workplace safety and reduce musculoskeletal injuries.

dorsaVi Expands AI Platform into Workplace Safety Market

dorsaVi has expanded its AI-powered movement analysis platform, Video AI, into the workplace ergonomics market, partnering with a major US franchise group and a leading Australian insurer. This strategic move allows dorsaVi to leverage its scalable, high-margin Video AI platform to enter the multibillion-dollar workplace safety and injury prevention market, marking a significant milestone in the company’s product evolution.

dorsaVi Advances AI Movement Analysis and Launches New ACL Injury Test

dorsaVi Limited has reported significant progress in the commercial release of its AI-powered Video Movement Analysis Platform, gaining traction in the US market. The company has achieved sales revenue of $289k and is advancing security clearances with a major US clinical group, which could expand its market presence. Additionally, dorsaVi has launched a pioneering 3D motion analysis test to address ACL injuries, potentially setting a new standard in sports medicine. A new research collaboration with a prominent US surgeon aims to optimize movement analysis for elite athletes, further reinforcing dorsaVi’s leadership in data security and injury prevention.

dorsaVi Limited Announces Cessation of Securities

dorsaVi Limited announced the cessation of 4,801,827 securities due to the expiry of options or other convertible securities without exercise or conversion. This development may impact the company’s capital structure and could influence investor perceptions regarding the company’s financial strategies.

dorsaVi Unveils Revolutionary 3D Motion Analysis to Combat ACL Injuries

dorsaVi has launched a groundbreaking 3D motion analysis test designed to reduce ACL injuries in athletes. This innovative tool, which utilizes FDA-cleared wearable sensors and advanced AI, offers a significant improvement over traditional 1D force plates by capturing critical rotational torque forces. The new technology is expected to open substantial market opportunities in elite sports, rehabilitation centers, and physiotherapy clinics, enabling real-time, laboratory-grade analysis for proactive injury prevention and rehabilitation strategies.